Stonepine Capital Management, LLC - Q3 2023 holdings

$301 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 38.1% .

 Value Shares↓ Weighting
BuyQUIDELORTHO CORP$48,118,314
-6.2%
658,794
+6.4%
15.98%
-13.7%
EOLS BuyEVOLUS INC$47,336,097
+44.5%
5,179,004
+14.9%
15.72%
+33.1%
BuyAMYLYX PHARMACEUTICALS INC$46,065,543
+90.5%
2,515,868
+124.4%
15.30%
+75.5%
ADMA BuyADMA BIOLOGICS INC$32,593,305
+0.4%
9,104,275
+3.5%
10.83%
-7.5%
GLPG BuyGALAPAGOS NV-SPON ADRspons adr$27,727,895
-0.1%
802,544
+17.6%
9.21%
-8.0%
NewALIMERA SCIENCES INC$12,349,4273,983,686
+100.0%
4.10%
SellMAXCYTE INC$11,736,317
-35.5%
3,761,640
-5.2%
3.90%
-40.6%
BuyXERIS BIOPHARMA HOLDINGS INC$11,002,592
-23.6%
5,915,372
+7.5%
3.66%
-29.7%
GMDA BuyGAMIDA CELL LTD$8,204,841
+183.4%
7,965,865
+431.1%
2.73%
+161.1%
LIFE SellATYR PHARMA INC$7,310,066
-26.9%
4,626,624
-0.0%
2.43%
-32.6%
SCYX SellSCYNEXIS INC$6,503,926
-25.2%
2,852,599
-3.2%
2.16%
-31.1%
XOMA BuyXOMA CORP$6,151,722
-6.8%
436,602
+25.0%
2.04%
-14.2%
XFOR BuyX4 PHARMACEUTICALS INC$5,748,317
-35.7%
5,273,685
+14.5%
1.91%
-40.7%
AVIR BuyATEA PHARMACEUTICALS INC$5,160,000
+83.4%
1,720,000
+128.7%
1.71%
+68.9%
RZLT  REZOLUTE INC$4,055,668
-33.3%
3,072,4760.0%1.35%
-38.6%
TELA BuyTELA BIO INC$3,935,352
-19.5%
491,919
+1.9%
1.31%
-25.9%
XGN BuyEXAGEN INC$2,912,448
-4.3%
1,203,491
+14.7%
0.97%
-11.9%
NewIO BIOTECH INC$2,785,1841,975,308
+100.0%
0.92%
GOSS NewGOSSAMER BIO INC$2,781,0563,339,405
+100.0%
0.92%
DCTH BuyDELCATH SYSTEMS INC$2,779,272
+32.5%
686,240
+81.2%
0.92%
+21.9%
ASRT NewASSERTIO HOLDINGS INC$2,435,064951,197
+100.0%
0.81%
VNDA NewVANDA PHARMACEUTICALS INC$2,064,541477,903
+100.0%
0.69%
 AYTU BIOPHARMA INC$1,275,396
+68.8%
472,3690.0%0.42%
+55.3%
CSTL ExitCASTLE BIOSCIENCES INC$0-91,978
-100.0%
-0.46%
URGN ExitUROGEN PHARMA LTD$0-448,508
-100.0%
-1.67%
ExitTHIRD HARMONIC BIO INC$0-2,793,149
-100.0%
-4.85%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CTI Biopharmap Corp.24Q1 202314.8%
APOLLO ENDOSURGERY INC23Q1 202315.6%
XOMA CORP20Q3 20235.7%
Cumberland Pharmaceuticals, Inc.19Q4 20207.0%
Amarin Corp PLC - SPONS ADR14Q3 202223.2%
VANDA PHARMACEUTICALS INC14Q3 202320.9%
BIODELIVERY SCIENCES INTL14Q1 202012.9%
AFFIMED NV13Q3 20227.7%
ALIMERA SCIENCES INC13Q3 20194.2%
VIVEVE MEDICAL INC12Q2 201915.3%

View Stonepine Capital Management, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Stonepine Capital Management, LLC Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CTI BIOPHARMA CORPApril 13, 20237,018,0465.3%
ADMA BIOLOGICS, INC.February 13, 20236,940,0003.1%
Amryt Pharma plcFebruary 13, 202331,666,1959.9%
Apollo Endosurgery, Inc.February 13, 20234,351,0889.0%
Conformis IncFebruary 13, 2023748,1949.9%
Ovid Therapeutics Inc.Sold outFebruary 13, 202300.0%
Adamas Pharmaceuticals IncSold outFebruary 14, 202200.0%
CATALYST BIOSCIENCES, INC.Sold outFebruary 14, 202200.0%
Conformis IncFebruary 14, 202214,768,8237.9%
YUMANITY THERAPEUTICS, INC.Sold outFebruary 14, 202200.0%

View Stonepine Capital Management, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13

View Stonepine Capital Management, LLC's complete filings history.

Compare quarters

Export Stonepine Capital Management, LLC's holdings